On Thursday 30 March, the European Commission authorised the Covid-19 mRNA vaccine Bimervax developed by HIPRA Human Health S.L.U. (see EUROPE B12922A21) as a booster dose for people aged 16 years and older, who have previously received a Covid-19 mRNA vaccination.
The vaccine is suitable for both Alpha and Beta variants of SARS-CoV-2.
This authorisation is based on the positive recommendation of the European Medicines Agency (EMA) of 30 March for the approval of the vaccine.
Indeed,...